Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EUAdvanced commercialization globally, signing ...
Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s ...
2-Year U.S. Treasury Note Continuous Contract $103.695 0.105 0.10% 5-Year U.S. Treasury Note Continuous Contract $108.453 0.266 0.25% 10-Year U.S. Treasury Note Continuous Contract $111.594 0.391 ...
3h
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 ...
The PGIM Jennison Focused Growth Fund rose 5.7%, slightly underperforming the Russell 1000 Growth Index. Click here to read ...
Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced that a major U.S. multi-line insurer has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback